Novartis and Glaxo Agree to Big Deal

The pharmaceutical companies announce a suite of asset swaps that drove up share prices and will reshape both.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, BRADLEY JSwiss pharmaceutical giant Novartis and British firm GlaxoSmithKline (GSK) traded more than $20 billion worth of assets today (April 22) in a series of deals that will overhaul both companies. Novartis will buy GSK’s oncology business for an estimated $16 billion, and GSK will purchase Novartis’s vaccine division for $7.1 billion. In addition, the two companies will combine forces on the direct-to-consumer ends of their businesses, with Novartis folding its over-the-counter pharmaceuticals in with GSK’s consumer product line.

“This is about getting us into fighting shape for the next 10 years,” Novartis’s chief executive Joseph Jimenez told The New York Times. Novartis is also selling its animal health division to Eli Lilly for more than $5 billion, according to The Guardian.

“Opportunities to build greater scale and combine high quality assets in vaccines and consumer healthcare are scarce,” GSK CEO Andrew Witty said in a statement. “With this transaction we will substantially strengthen two of our core businesses and create significant new options to increase value for shareholders."

Shares in both companies rose upon announcement of the deals on Tuesday: GSK added 5 percent, Novartis added 2 percent.

The announcement of Novartis’s and GSK’s extensive transactions comes during a busy year for such wheeling and dealing in the pharmaceutical sector. Earlier this year, Irish drug maker Mallinckrodt Pharmaceuticals bought Questcor Pharmaceuticals for $5.6 billion in cash and shares, and acquired Cadence Pharmaceuticals of San Diego for about $1.4 billion. And health-care company McKesson Corporation took over ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
3D illustration of a gold lipid nanoparticle with pink nucleic acid inside of it. Purple and teal spikes stick out from the lipid bilayer representing polyethylene glycol.
February 2025, Issue 1

A Nanoparticle Delivery System for Gene Therapy

A reimagined lipid vehicle for nucleic acids could overcome the limitations of current vectors.

View this Issue
Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

Enhancing Therapeutic Antibody Discovery with Cross-Platform Workflows

sartorius logo
Considerations for Cell-Based Assays in Immuno-Oncology Research

Considerations for Cell-Based Assays in Immuno-Oncology Research

Lonza
An illustration of animal and tree silhouettes.

From Water Bears to Grizzly Bears: Unusual Animal Models

Taconic Biosciences
Sex Differences in Neurological Research

Sex Differences in Neurological Research

bit.bio logo

Products

Photo of a researcher overseeing large scale production processes in a laboratory.

Scaling Lentiviral Vector Manufacturing for Optimal Productivity

Thermo Fisher Logo
An illustration of an mRNA molecule in front of a multicolored background.

Generating High-Quality mRNA for In Vivo Delivery with lipid nanoparticles

Thermo Fisher Logo
Tecan Logo

Tecan introduces Veya: bringing digital, scalable automation to labs worldwide

Explore a Concise Guide to Optimizing Viral Transduction

A Visual Guide to Lentiviral Gene Delivery

Takara Bio